Health on MSN3d
What To Know About Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Medically reviewed by Qin Rao, MD Metabolic dysfunction-associated steatohepatitis (MASH)—previously known as nonalcoholic ...
pharmaphorum7d
Gilead NASH drug fails late stage trial
The drug, an apoptosis signal-regulating kinase 1 (ASK1) inhibitor, did not meet the primary endpoint of a ≥ 1-stage histologic improvement in fibrosis without worsening of NASH in the STELLAR-4 ...
Tahoe Daily Tribune6d
Non-alcoholic fatty liver disease
The liver is essential for digestion, metabolism, detoxification, and fluid regulation. While alcohol abuse is a known cause ...
pharmaphorum1d
Another NASH setback as Akero’s efruxifermin stumbles
including that 4% of patients who received its drug at either dose had a two- or three-stage improvement in fibrosis with no worsening NASH, which was not seen in any patient in the placebo group.
Medical Xpress on MSN9d
Researchers identify a gene to guide novel therapeutics of nonalcoholic fatty liver diseases
Investigators have found that the gene Asah1 plays a crucial protective role in preventing the progression of nonalcoholic ...
Fatty liver disease without symptoms? Here’s how to catch it before it is too late
Non-alcoholic fatty liver disease has no early signs. Is your liver at risk? Expert reveals these simple tests could save your life!
Nonalcoholic Steatohepatitis Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Promising Nonalcoholic Steatohepatitis Therapies such as AZD2693, Saroglitazar Magnesium 4 mg, Semaglutide (SEMA), Cilofexor ...
EurekAlert!10d
Researchers identify a gene to guide novel therapeutics of nonalcoholic fatty liver diseases
About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even ...